Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Depreciation and Depletion: 2022-2025

Historic Depreciation and Depletion for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $200,000.

  • Taysha Gene Therapies' Depreciation and Depletion fell 33.33% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 16.36%. This contributed to the annual value of $1.2 million for FY2024, which is 11.07% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Depreciation and Depletion is $200,000, which was down 33.33% from $300,000 recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Depreciation and Depletion high stood at $400,000 for Q2 2023, and its period low was $200,000 during Q3 2025.
  • For the 3-year period, Taysha Gene Therapies' Depreciation and Depletion averaged around $314,091, with its median value being $300,000 (2025).
  • In the last 5 years, Taysha Gene Therapies' Depreciation and Depletion soared by 33.33% in 2023 and then slumped by 33.33% in 2025.
  • Over the past 4 years, Taysha Gene Therapies' Depreciation and Depletion (Quarterly) stood at $390,000 in 2022, then grew by 1.28% to $395,000 in 2023, then decreased by 23.04% to $304,000 in 2024, then tumbled by 33.33% to $200,000 in 2025.
  • Its Depreciation and Depletion was $200,000 in Q3 2025, compared to $300,000 in Q2 2025 and $300,000 in Q1 2025.